Phase II study of flutamide in the treatment of hepatocellular carcinoma

Yee Chao, Wing Kai Chan, Yi Shin Huang, Ho Chung Teng, Sun Sang Wang, Wing Yiu Lui, Jacqueline Whang-Peng, Shou Dong Lee

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

BACKGROUND. Hepatocellular carcinoma (HCC) is a male predominant disease and may be an androgen-dependent or androgen-responsive tumor. This Phase II study was designed to investigate the clinical activity and toxicity of flutamide in the treatment of patients with advanced HCC. METHODS. Thirty- two patients with measurable advanced HCC were studied. Flutamide, 750 mg per day, was administered orally for 8 weeks. Ten patients died before repeat tumor measurements could be performed. RESULTS. Twenty-two patients were evaluable for response and toxicities. There were no complete responses nor partial responses. Nine of 22 patients (41%) had stable disease and 13 patients (59%) had progressive disease. Serum alpha-fetoprotein was reduced in three patients. The median survival was 10 weeks (range, one to 35 weeks). Toxicities were minimal and tolerable. CONCLUSIONS. Flutamide is not effective in the treatment of advanced HCC. Clinically, HCC may not be an androgen-responsive tumor. Other new methods of treatment of HCC warrants future clinical investigations.

Original languageEnglish
Pages (from-to)635-639
Number of pages5
JournalCancer
Volume77
Issue number4
DOIs
Publication statusPublished - Feb 15 1996
Externally publishedYes

Fingerprint

Flutamide
Hepatocellular Carcinoma
Androgens
Therapeutics
Neoplasms
alpha-Fetoproteins
Survival
Serum

Keywords

  • antiandrogen
  • flutamide
  • hepatocellular carcinoma
  • hormonal therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Chao, Y., Chan, W. K., Huang, Y. S., Teng, H. C., Wang, S. S., Lui, W. Y., ... Lee, S. D. (1996). Phase II study of flutamide in the treatment of hepatocellular carcinoma. Cancer, 77(4), 635-639. https://doi.org/10.1002/(SICI)1097-0142(19960215)77:4<635::AID-CNCR8>3.0.CO;2-F

Phase II study of flutamide in the treatment of hepatocellular carcinoma. / Chao, Yee; Chan, Wing Kai; Huang, Yi Shin; Teng, Ho Chung; Wang, Sun Sang; Lui, Wing Yiu; Whang-Peng, Jacqueline; Lee, Shou Dong.

In: Cancer, Vol. 77, No. 4, 15.02.1996, p. 635-639.

Research output: Contribution to journalArticle

Chao, Yee ; Chan, Wing Kai ; Huang, Yi Shin ; Teng, Ho Chung ; Wang, Sun Sang ; Lui, Wing Yiu ; Whang-Peng, Jacqueline ; Lee, Shou Dong. / Phase II study of flutamide in the treatment of hepatocellular carcinoma. In: Cancer. 1996 ; Vol. 77, No. 4. pp. 635-639.
@article{e69fdd25ce144044a57aa09cf9051858,
title = "Phase II study of flutamide in the treatment of hepatocellular carcinoma",
abstract = "BACKGROUND. Hepatocellular carcinoma (HCC) is a male predominant disease and may be an androgen-dependent or androgen-responsive tumor. This Phase II study was designed to investigate the clinical activity and toxicity of flutamide in the treatment of patients with advanced HCC. METHODS. Thirty- two patients with measurable advanced HCC were studied. Flutamide, 750 mg per day, was administered orally for 8 weeks. Ten patients died before repeat tumor measurements could be performed. RESULTS. Twenty-two patients were evaluable for response and toxicities. There were no complete responses nor partial responses. Nine of 22 patients (41{\%}) had stable disease and 13 patients (59{\%}) had progressive disease. Serum alpha-fetoprotein was reduced in three patients. The median survival was 10 weeks (range, one to 35 weeks). Toxicities were minimal and tolerable. CONCLUSIONS. Flutamide is not effective in the treatment of advanced HCC. Clinically, HCC may not be an androgen-responsive tumor. Other new methods of treatment of HCC warrants future clinical investigations.",
keywords = "antiandrogen, flutamide, hepatocellular carcinoma, hormonal therapy",
author = "Yee Chao and Chan, {Wing Kai} and Huang, {Yi Shin} and Teng, {Ho Chung} and Wang, {Sun Sang} and Lui, {Wing Yiu} and Jacqueline Whang-Peng and Lee, {Shou Dong}",
year = "1996",
month = "2",
day = "15",
doi = "10.1002/(SICI)1097-0142(19960215)77:4<635::AID-CNCR8>3.0.CO;2-F",
language = "English",
volume = "77",
pages = "635--639",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Phase II study of flutamide in the treatment of hepatocellular carcinoma

AU - Chao, Yee

AU - Chan, Wing Kai

AU - Huang, Yi Shin

AU - Teng, Ho Chung

AU - Wang, Sun Sang

AU - Lui, Wing Yiu

AU - Whang-Peng, Jacqueline

AU - Lee, Shou Dong

PY - 1996/2/15

Y1 - 1996/2/15

N2 - BACKGROUND. Hepatocellular carcinoma (HCC) is a male predominant disease and may be an androgen-dependent or androgen-responsive tumor. This Phase II study was designed to investigate the clinical activity and toxicity of flutamide in the treatment of patients with advanced HCC. METHODS. Thirty- two patients with measurable advanced HCC were studied. Flutamide, 750 mg per day, was administered orally for 8 weeks. Ten patients died before repeat tumor measurements could be performed. RESULTS. Twenty-two patients were evaluable for response and toxicities. There were no complete responses nor partial responses. Nine of 22 patients (41%) had stable disease and 13 patients (59%) had progressive disease. Serum alpha-fetoprotein was reduced in three patients. The median survival was 10 weeks (range, one to 35 weeks). Toxicities were minimal and tolerable. CONCLUSIONS. Flutamide is not effective in the treatment of advanced HCC. Clinically, HCC may not be an androgen-responsive tumor. Other new methods of treatment of HCC warrants future clinical investigations.

AB - BACKGROUND. Hepatocellular carcinoma (HCC) is a male predominant disease and may be an androgen-dependent or androgen-responsive tumor. This Phase II study was designed to investigate the clinical activity and toxicity of flutamide in the treatment of patients with advanced HCC. METHODS. Thirty- two patients with measurable advanced HCC were studied. Flutamide, 750 mg per day, was administered orally for 8 weeks. Ten patients died before repeat tumor measurements could be performed. RESULTS. Twenty-two patients were evaluable for response and toxicities. There were no complete responses nor partial responses. Nine of 22 patients (41%) had stable disease and 13 patients (59%) had progressive disease. Serum alpha-fetoprotein was reduced in three patients. The median survival was 10 weeks (range, one to 35 weeks). Toxicities were minimal and tolerable. CONCLUSIONS. Flutamide is not effective in the treatment of advanced HCC. Clinically, HCC may not be an androgen-responsive tumor. Other new methods of treatment of HCC warrants future clinical investigations.

KW - antiandrogen

KW - flutamide

KW - hepatocellular carcinoma

KW - hormonal therapy

UR - http://www.scopus.com/inward/record.url?scp=0030056276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030056276&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19960215)77:4<635::AID-CNCR8>3.0.CO;2-F

DO - 10.1002/(SICI)1097-0142(19960215)77:4<635::AID-CNCR8>3.0.CO;2-F

M3 - Article

C2 - 8616754

AN - SCOPUS:0030056276

VL - 77

SP - 635

EP - 639

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -